ethyl (E)-3-(4-methoxy-7-nitro-1,3-benzodioxol-5-yl)prop-2-enoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (E)-3-(4-methoxy-7-nitro-1,3-benzodioxol-5-yl)prop-2-enoate
• 化学式: C13H13NO7
• 分子量: 295.24
• InChiKey: NHALCSNNUZQBOY-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  99.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1
  申请人：PHUSIS THERAPEUTICS, INC.

  公开号：US20150307482A1

  公开（公告）日：2015-10-29

  Embodiments include compositions and methods of inhibiting CNKSR1 and methods of identifying inhibitors of CNKSR1.
• COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1
  申请人：Phusis Therapeutics, Inc.

  公开号：US20160304533A1

  公开（公告）日：2016-10-20

  Compounds that inhibit CNKSR1, pharmaceutical compositions including compounds that inhibit CNKSR1 and methods of treating disease or disorders that respond to CNKSR1 inhibition are described herein. Additionally, methods of identifying inhibitors of CNKSR1 are described.
• US9340532B2
  申请人：——

  公开号：US9340532B2

  公开（公告）日：2016-05-17
• [EN] METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR L'INHIBITION DE CNKSR1
  申请人：PHUSIS THERAPEUTICS INC

  公开号：WO2014093988A2

  公开（公告）日：2014-06-19

  Embodiments include compositions and methods of inhibiting CNKSR1 and methods of identifying inhibitors of CNKSR1.